This Article  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Gloria Koch, RN; John P. Allen, MD
University of Illinois College of Medicine at Peoria 530 NE Glen Oak Ave Peoria, IL 61637

Robert J. Joynt, MD, PhD
Chief Editor

Arch Neurol. 1987;44(6):578-579.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The recent use of pharmacokinetic parameters and serum anticonvulsant testing has resulted in better management of patients with seizure disorders who require anticonvulsant therapy. The availability of certain anticonvulsants from different pharmaceutical manufacturers has resulted in increased difficulty in optimally treating such individuals. Recently, generic forms of carbamazepine have become available and we wish to report decreased serum carbamazepine levels in one subject using therapy with a generic compound.

Report of a Case.

—A 30-year-old woman with confirmed partial complex seizures, well-controlled on carbamazepine (Tegretol) therapy, with stable morning predose anticonvulsant levels (Nov 12, 1985, 8400 mg/L [35557 µmol/L]; April 5, 1986, 9700 mg/L [41 060 µmol/L]; and May 5, 1986, 7300 mg/L [30 900 µmol/L], at a rate of 400 mg/24 h), was recently started on generic carbamazepine (Goldline) therapy. Following initiation of generic carbamazepine therapy, increased seizure activity was noted. A serum carbamazepine level was . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?